First-line carboplatin plus pemetrexed with pemetrexed maintenance in HIV-positive patients with advanced non-squamous non-small cell lung cancer: the phase II IFCT-1001 CHIVA trial
- 1 August 2020
- journal article
- research article
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 56 (2), 1902066
- https://doi.org/10.1183/13993003.02066-2019
Abstract
HIV infection is an exclusion criterion in lung cancer trials. This multicentre phase II trial aimed to assess feasibility, efficacy and safety of first-line carboplatin plus pemetrexed (CaP) followed by pemetrexed (P) maintenance in people living with HIV (PLHIV) with advanced non-squamous non-small cell lung cancer (NS-NSCLC). Four cycles of CaP were followed by P-maintenance therapy in patients with Eastern Cooperative Oncology Group performance status <= 2. The primary objective was a disease control rate (DCR) >= 30% after 12 weeks. Of the 61 PLHIV enrolled, 49 (80%) had a performance status of 0-1, and 19 (31%) had brain metastases. Median CD4 lymphocyte count was 418 cells.mu L-1 (range 18-1230), median CD4 lymphocyte nadir was 169.5 cells.mu L-1 (1-822); 48 (80%) patients were virologically controlled. Four-cycle inductions were achieved by 38 (62%) patients, and 31 (51%) started P-maintenance (median of 4.1 cycles (range 1-19)). The 12-week DCR was 50.8% (95% CI 38.3-63.4) and partial response rate 21.3%. Median progression-free survival and overall survival were 3.5 (95% CI 2.7-4.4) and 7.6 months (5.7-12.8), respectively. Patients with a performance status of 0-1 had the longest median progression-fire survival (4.3 months, 95% CI 3.1-5.2) and overall survival (11.9 months, 95% CI 6.4-14.3). During induction, CaP doublet was well tolerated apart from grade 3-4 haematological toxicities (neutmpenia 53.8%; thrombocytopenia 35.0%; anaemia 30.0%). Two fatal treatment-related sepses were reported. No opportunistic infections were experienced. In PLHIV with advanced NS-NSCLC, first-line four-cycle CaP induction followed by P-maintenance was effective and reasonably well-tolerated. Further studies should evaluate combination strategies of CaP with immunotherapy in PLHIV.Funding Information
- Ligue Contre le Cancer
- Eli Lilly and Company
This publication has 43 references indexed in Scilit:
- HIV as an independent risk factor for incident lung cancerAIDS, 2012
- Lung Cancer in HIV InfectionClinical Lung Cancer, 2012
- Use of antineoplastic agents in patients with cancer who have HIV/AIDSThe Lancet Oncology, 2011
- Human Immunodeficiency Virus Infection and Non-small Cell Lung Cancer: Survival and Toxicity of Antineoplastic Chemotherapy in a Cohort StudyJournal of Thoracic Oncology, 2011
- Lung Cancer in HIV-Positive PatientsJournal of Thoracic Oncology, 2010
- Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort studyThe Lancet Oncology, 2009
- CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatmentSeminars in Radiation Oncology, 2003
- Recovery of Hematopoietic Activity in Bone Marrow from Human Immunodeficiency Virus Type 1-Infected Patients during Highly Active Antiretroviral TherapyAIDS Research and Human Retroviruses, 2000
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- Quality of life assessment in individuals with lung cancer: Testing the Lung Cancer Symptom Scale (LCSS)European Journal of Cancer, 1993